Literature DB >> 16680602

Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?

Electron Kebebew1, Emily Reiff, Quan-Yang Duh, Orlo H Clark, Alex McMillan.   

Abstract

BACKGROUND: Adrenocortical carcinoma (ACC), a rare and aggressive malignancy, accounts for up to 14% of adrenal incidentalomas. The only chance of cure for ACC is diagnosis at an early stage; therefore, a main indication for adrenalectomy in patients with adrenal incidentaloma has been the potential risk of ACC. Recent studies suggest that this has led to earlier stage of ACC at diagnosis, more curative operations, and better survival.
METHODS: We analyzed data on ACC from The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. Four equal time quartiles (1973-1979, 1980-1986, 1987-1993, and 1994-2000) were compared for changes in demographics, pathology, treatment, and cause-specific mortality.
RESULTS: The average age was 51.2 years (range: 1-97), and 45.9% of patients were men. The average tumor size was 12 cm (range: 2-36 cm), and only 4.2% were < or = 6 cm. Most (88%) patients had surgical resection of their tumor, and external beam radiotherapy was used in only 12% of patients. Between the time quartiles compared (as well as annually), there was no significant difference at presentation in age at diagnosis, sex, race/ethnicity, tumor size, tumor grade, the frequency of distant metastasis, and overall TNM stage. Low tumor grade, lower stage of ACC, later time quartile, and surgical resection were associated with a lower cause-specific mortality by univariate analysis (P < or = 0.002) and by multivariate analysis (P < or = 0.031).
CONCLUSIONS: Although adrenal incidentalomas have become a common indication for adrenalectomy, this has not resulted in patients with ACC being diagnosed earlier or treated at a lower stage of disease at the national level. The most important predictors of survival in these patients are tumor grade, tumor stage, and surgical resection.

Entities:  

Mesh:

Year:  2006        PMID: 16680602     DOI: 10.1007/s00268-005-0329-x

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  20 in total

1.  Report examines association between cancer and socioeconomic status.

Authors:  Tom Reynolds
Journal:  J Natl Cancer Inst       Date:  2003-10-01       Impact factor: 13.506

2.  Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia.

Authors:  Nina S Kadan-Lottick; Kirsten K Ness; Smita Bhatia; James G Gurney
Journal:  JAMA       Date:  2003-10-15       Impact factor: 56.272

3.  Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy.

Authors:  Florence de Fraipont; Michelle El Atifi; Nadia Cherradi; Gwennaelle Le Moigne; Geneviève Defaye; Rémi Houlgatte; Jérôme Bertherat; Xavier Bertagna; Pierre-François Plouin; Eric Baudin; François Berger; Christine Gicquel; Olivier Chabre; Jean-Jacques Feige
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

4.  Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma.

Authors:  R D Schulick; M F Brennan
Journal:  Ann Surg Oncol       Date:  1999-12       Impact factor: 5.344

5.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.

Authors:  P Icard; P Goudet; C Charpenay; B Andreassian; B Carnaille; Y Chapuis; P Cougard; J F Henry; C Proye
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 6.  Adrenocortical carcinoma: clinical and laboratory observations.

Authors:  B L Wajchenberg; M A Albergaria Pereira; B B Medonca; A C Latronico; P Campos Carneiro; V A Alves; M C Zerbini; B Liberman; G Carlos Gomes; M A Kirschner
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

7.  Adrenocortical carcinoma: surgical progress or status quo?

Authors:  M L Kendrick; R Lloyd; L Erickson; D R Farley; C S Grant; G B Thompson; C Rowland; W F Young; J A van Heerden
Journal:  Arch Surg       Date:  2001-05

8.  Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection.

Authors:  L E Harrison; P B Gaudin; M F Brennan
Journal:  Arch Surg       Date:  1999-02

Review 9.  Treatment of adrenocortical carcinoma: contemporary outcomes.

Authors:  David Y T Chen; R Ernest Sosa; Douglas S Scherr
Journal:  Curr Urol Rep       Date:  2004-02       Impact factor: 2.862

10.  Nuclear DNA content and morphological characteristics in the prognosis of adrenocortical carcinoma.

Authors:  H R Haak; C J Cornelisse; J Hermans; L Cobben; G J Fleuren
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more
  125 in total

Review 1.  5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications.

Authors:  Sarika N Rao; Mouhammed Amir Habra
Journal:  Horm Cancer       Date:  2015-12-10       Impact factor: 3.869

2.  Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.

Authors:  Kei Satoh; Lisa Zhang; Yaqin Zhang; Raju Chelluri; Myriem Boufraqech; Naris Nilubol; Dhaval Patel; Min Shen; Electron Kebebew
Journal:  Clin Cancer Res       Date:  2016-02-12       Impact factor: 12.531

3.  The impact of patient-, disease-, and treatment-related factors on survival in patients with adrenocortical carcinoma.

Authors:  Nahid Punjani; Roderick Clark; Jonathan Izawa; Joseph Chin; Stephen E Pautler; Nicholas Power
Journal:  Can Urol Assoc J       Date:  2017-12-22       Impact factor: 1.862

4.  Management and prognosis of adrenocortical tumors in children: can we find out an appropriate points-scoring system to predict prognosis?

Authors:  Wei Ru; Min Yang; Shan Xu; Minju Li; Daxing Tang
Journal:  Pediatr Surg Int       Date:  2017-03-04       Impact factor: 1.827

5.  Actual 10-year survivors following resection of adrenocortical carcinoma.

Authors:  Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason D Prescott; Tracy S Wang; Jason Glenn; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Ioannis Hatzaras; Rivfka Shenoy; Timothy M Pawlik; Jeffrey A Norton; George A Poultsides
Journal:  J Surg Oncol       Date:  2016-09-16       Impact factor: 3.454

6.  Adrenal Surgery for Synchronously Metastatic Adrenocortical Carcinoma: A Population-Based Analysis.

Authors:  Kan Wu; Zhihong Liu; Xiang Li; Yiping Lu
Journal:  World J Surg       Date:  2021-01-22       Impact factor: 3.352

Review 7.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

8.  TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.

Authors:  Meenu Jain; Lisa Zhang; Mei He; Ya-Qin Zhang; Min Shen; Electron Kebebew
Journal:  Endocr Relat Cancer       Date:  2013-05-21       Impact factor: 5.678

9.  Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence.

Authors:  Neda Amini; Georgios Antonios Margonis; Yuhree Kim; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2015-08-18       Impact factor: 5.344

10.  Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes.

Authors:  Georgios Antonios Margonis; Yuhree Kim; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2015-08-19       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.